BioSpace News Archive

Rakovina Therapeutics Inc. is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference.

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company’s leading three-dimension heart mapping system used in cardiac ablation procedures.

Lipocine Inc., a biopharmaceutical company, announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver Congress, to take place June 5 to 8, 2024 in Milan, Italy.

Twist Bioscience Corporation today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Immunome, Inc. today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.

Precision BioSciences, Inc. today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team.

Aadi Bioscience today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Solarea Bio, a Boston-based clinical-stage biotechnology company, recognizes this and believes that it is essential to not only raise awareness around the importance of bone health far ahead of menopause, but to also provide consumers with tangible avenues for managing bone loss leading up to and throughout the menopausal experience.

TiumBio Co., Ltd. announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain.